FDA approves overdose-reversing Narcan for over-the-counter sale
Comments on how OTC naloxone isn’t enough to address issues with access.
Published:
Last updated:
Jonathan JK Stoltman (PhD)
Jonathan JK Stoltman, PhD is Director of the Opioid Policy Institute. They have been an addiction scientist since 2013. Their work has appeared in leading academic journals and in the media.
All articlesMore in In the News
See all
![The Current [Lafayette, Louisiana] (4 Dec 2025)](https://storage.ghost.io/c/96/d5/96d508b5-cdb3-41b4-8b42-c402c3098b68/content/images/size/w960/format/webp/2025/12/zen_nPMHyjX6fZ.png)
More from Jonathan JK Stoltman (PhD)
See all
/
Members-only
DEA Takeback Day (Come and Take It!🐍)
/
Members-only
⁉️61% of VA.gov links on FindTreatment.gov are BROKEN
